Open AccessS100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE‐AGENT CONTINUATION IN PATIENTS AGED 18‐75 YEARS WITH NEWLY DIAGNOSED FLT3‐ITD+ AML
Author(s) -
Erba H.,
Montesinos P.,
Vrhovac R.,
Patkowska E.,
Kim H.J.,
Zak P.,
Wang P.N.,
Mitov T.,
Hanyok J.,
Liu L.,
Benzohra A.,
Lesegretain A.,
Cortes J.,
Perl A.,
Sekeres M.,
Dombret H.,
Amadori S.,
Wang J.,
Levis M.,
Schlenk R.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843296.73803.85
Subject(s) - medicine , cytarabine , idarubicin , gastroenterology , mucositis , placebo , surgery , chemotherapy , pathology , alternative medicine